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Objective: The synovial fluid (SF) of patients with focal cartilage defects contains a population of poorly charac-
terised cells that could have pathophysiological implications in early osteoarthritis and joint tissue repair. We
have examined the cells within SF of such joints by determining their chondrogenic capacity following culture
expansion and establishing the phenotypes of the macrophage subsets in non-cultured cells.
Design: Knee SF cells were obtained from 21 patients receiving cell therapy to treat a focal cartilage defect. Cell
surface immunoprofiling for stem cell and putative chondrogenic markers, and the expression analysis of key
chondrogenic and hypertrophic genes were conducted on culture-expanded SF cells prior to chondrogenesis. Flow
cytometry was also used to determine the macrophage subsets in freshly isolated SF cells.
Results: Immunoprofiling revealed positivity for the monocyte/macrophage marker (CD14), the haematopoietic/
endothelial cell marker (CD34) and mesenchymal stem/stromal cell markers (CD73, CD90, CD105) on culture
expanded cells. We found strong correlations between the presence of CD14 and the vascular cell adhesion
marker, CD106 (r ¼ 0.81, p ¼ 0.003). Collagen type II expression after culture expansion positively correlated
with GAG production (r ¼ 0.73, p ¼ 0.006), whereas CD90 (r ¼ 0.6, p ¼ 0.03) and CD105 (r ¼ 0.55, p ¼ 0.04)
immunopositivity were inversely related to GAG production. Freshly isolated SF cells were positive for both pro-
(CD86) and anti-inflammatory markers (CD163 and CD206).
Conclusions: The cellular content of the SF from patients with focal cartilage injuries is comprised of a hetero-
geneous population of reparative and inflammatory cells. Additional investigations are needed to understand the
role played by these cells in the attempted repair and inflammatory process in diseased joints.1. Introduction
A growing body of research has demonstrated that joint degeneration
in osteoarthritis (OA) is not only due to mechanical attrition (through
progressive wear or trauma) but is also facilitated, at least in part, by an
inflammatory environment [1,2]. Focal defects of the cartilage in the
knee are associated with further degradation of cartilage and are a risk
factor for OA [3]; however the cellular events involved in this process aregnes Hunt, Orthopaedic Hospital




ier Ltd on behalf of Osteoarthritisstill poorly understood. The synovial fluid (SF), which contains both its
own population of cells and molecules produced by other joint tissues,
provides a means of evaluating the inflammatory status of the local
environment. Whilst molecules such as cytokines have been extensively
explored in the SF as potential biomarkers of OA [4], few studies have
investigated the cellular content of the SF, particularly in early OA [5].
Previous reports revealed the presence of immune cells, such as
macrophages, lymphocytes and natural killer cells, in the SF of non-, Keele University, Oswestry, Shropshire, SY10 7AG, United Kingdom.
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poorly understood innate immune system of the joint, that could hold
important information on OA pathophysiology, as well as therapeutic
targets at an early stage of disease progress and may contribute to disease
pathophysiology. The changes that occur in early OA affect the articular
cartilage (increased catabolic enzyme activity), subchondral bone (sub-
chondral bone remodelling and osteophyte formation), meniscus
(fibrillation of avascular region), synovium (hyperplasia and lymphocyte
infiltrates), tendons and menisci (ruptures and tears) [8].
A population of mesenchymal stem/stromal cells (MSCs) with chon-
drogenic potential has also been characterised from the knee SF (SF-
MSCs) [9] of early OA patients and their prevalence increases in the end
stages of the disease [10]. The biological properties and role of these
SF-MSCs in the early stages of OA development or attempted joint repair
is still unclear. The SF may also contain chondrocyte populations origi-
nating from cartilage fragments in a damaged articular joint. In the
present investigation, we firstly analysed the characteristics of plastic
adherent SF cells in culture from early OA patients for markers of
chondrogenesis, stem cells and immune cells. Secondly, the unexpected
presence of CD14 on the culture-expanded cells prompted us to deter-
mine the phenotype of these monocyte/macrophages in freshly isolated,
non-cultured, SF cells from patients receiving autologous cell implanta-
tion (ACI), a procedure recommended for patients with focal cartilage
defects but not end-stage OA.
2. Methods
2.1. Patients
Ethical approval was given by the National Research Ethics Service
(11/NW/0875) and all patients provided written informed consent
before SF was taken. Approximately 3–20 mL of SF were obtained via
arthrocentesis, as previously described [10], from the knees of 21 pa-
tients (13males, 8 females, mean age¼ 35 11 years) undergoing ACI to
treat focal cartilage defects assessed arthroscopically and using magnetic
resonance imaging (MRI) (Table 1). ACI involves a cartilage harvest from
a minor load bearing region of the joint (stage 1) and the implantation of
cells culture expanded from the biopsy, into the joint 2–3 weeks later
(stage 2). Patients included in this study had a focal cartilage defect,
while patients with end stage OA and a Kellgren-Lawrence (KL) score
above 2 were excluded from this study (average KL score ¼ 1.1  0.9).Table 1
Demographics of patients from which SF cells was obtained. Only non-cultured
cells were used for macrophage characterisation.
Patient
number






1 Male 22 35.0 638 2 Yes
2 Female 48 29.5 200 2 Yes
3 Male 21 37.6 225 0 Yes
4 Female 19 34.1 400 2 Yes
5 Male 36 23.6 450 2 Yes
6 Male 28 30.5 150 1 Yes
7 Male 28 27.0 105 2 Yes
8 Female 30 27.8 32 1 Yes
9 Male 47 26.6 250 0 Yes
10 Female 35 23.8 200 0 Yes
11 Male 29 19.4 110 2 Yes
12 Male 30 36.3 100 0 Yes
13 Female 36 21.1 150 0 Yes
14 Female 63 23.7 400 2 Yes
15 Female 42 25.0 360 2 Yes
16 Male 37 37.9 300 0 No
17 Male 27 28.0 250 1 No
18 Male 52 22.8 300 0 No
19 Male 27 24.8 500 2 No
20 Male 40 28.0 750 1 No
21 Female 46 34.0 300 1 No
2
2.2. Isolation of SF cells
The SFs were centrifuged at 800g for 15 min immediately after sur-
gical intervention and no evidence of heavy blood staining was found in
the samples. The supernatant was removed and the resulting pellet was
either resuspended in complete culture medium (n ¼ 15) comprised of
Dulbecco's Modified Eagle's Medium/F-12 (DMEM/F-12, Life Technolo-
gies) with 1% (v/v) penicillin/streptomycin (P/S, Life Technologies) and
10% (v/v) foetal bovine serum (FBS, Life Technologies) for monolayer
expansion, or prepared directly for flow cytometry.2.3. Multichromatic flow cytometry
Table 2 provides details of the clones, isotypes and fluorochromes of
all the antibodies used for flow cytometry in this study. A minimum of
10 000 cells were acquired and analysed for each marker. Cultured cells
were expanded by seeding at 5000 cells/cm2 and trypsinisation up to
passage 3, after which multichromatic flow cytometry using
fluorochrome-conjugated antibodies (all BD Biosciences) was used to
determine the positivity of certain immune cell markers (CD14-PercP-
Cy5.5, CD19-BV421, CD45-PE), the vascular cell adhesion marker
(CD106-APC), haematopoietic/endothelial/adipose cell marker (CD34-
APC), the major histocompatibility complex class II marker (HLA-DR-
APC), the MSC markers (CD90-PE, CD73-BV421 and CD105-APC), and
putative chondropotency markers (CD39-APC, CD44-PercP-Cy5.5 [11],
CD49c-PE [11], CD151-PE [11], CD166-BV421 [12], and CD271-BV421
[13]), were also examined as we described previously [14].
To explore the various subsets of macrophages in freshly isolated SF
cells from arthrocentesis (n ¼ 6) at baseline (prior to stage 1 of ACI,
which is the time of cartilage harvest) and 2–3 weeks later (prior to stage
2, which is the time of cell implantation), fluorochrome-conjugated an-
tibodies against the M2 markers CD206-BV421 and CD163- PerCP-Cy5.5
[15,16], and M1 markers CD80-PE and CD86-FITC [17,18], were used
together with the pan macrophage marker CD14-APC in multichromatic
flow cytometry. After immunostaining, the cells were incubated with a
haemolysis buffer (BD Biosciences) for 1 min to remove any red blood
cells. Matching fluorochrome-conjugated isotype controls were used for
each antibody (all BD Biosciences). For all flow cytometry analyses,
gating was first established (at 1% positivity) on the isotype controls and
then applied to the corresponding markers. Stage 1 and 2 cell samplesTable 2
Fluorochrome conjugated antibodies used for multichromatic flow cytometry.
Marker Antibody Clone Isotype control Fluorochrome
ISCTa MSC markers
CD73 AD2 Mouse IgG1 BV421
CD90 5E10 Mouse IgG1 PE
CD105 266 Mouse IgG1 APC
CD14 MϕP9 Mouse IgG2b PercP-Cy5.5
CD19 HIB19 Mouse IgG1 BV421
CD34 581 Mouse IgG1 APC
CD45 HI30 Mouse IgG1 PE
HLA-DR TU36 Mouse IgG2b APC
Chondropotency markers
CD44 G44-26 Mouse IgG2b PercP-Cy5.5
CD166 3A6 Mouse IgG1 BV421
CD49c C3 II.1 Mouse IgG1 PE
CD106 51-10C9 Mouse IgG1 APC
CD151 14A2.H1 Mouse IgG1 PE
CD39 TU66 Mouse IgG2b APC
CD271 C40-1457 Mouse IgG1 BV421
Macrophage markers
CD14 (pan marker) M5E2 Mouse IgG2a APC
CD80 (M1) L307.4 Mouse IgG1 PE
CD86 (M1) 2331 (FUN-1) Mouse IgG1 FITC
CD206 (M2) 19.2 Mouse IgG1 BV421
CD163 (M2) GHI/61 Mouse IgG1 PerCP-Cy5.5
a ISCT: International Society for Cellular Therapy.
Fig. 1. A) Flow cytometry was used to determine the MSC cell surface immu-
noprofile of SF cells (P3), before chondrogenic induction. This panel consists of
MSC markers (CD73, CD90, and CD105, n ¼ 15) as well as immune cell markers
(CD14, CD106, CD19, CD45 and HLA-DR, n ¼ 10) and one haematopoietic
marker (CD34, n ¼ 10). (B) Flow cytometry was also used to determine the
percentage of SF cells that were positive for surface markers known to be
indicative of chondrogenic potency. (C) The expression of chondrogenic (SOX9,
ACAN, COL2, and FRZB) and hypertrophic (COL10A1 and ALK1) genetic
markers was determine by qRT-PCR, with PPIA and TBP used as reference genes
(n ¼ 14). Scatter plots show medians with interquartile ranges, with each dot
representing a patient.
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first gated as part of the total cell population. The M1 and M2 positive
cells were gated individually and as double positive combinations within
the CD14þ cells. All gate cut-offs were established based on isotype
controls (1%).
2.4. RNA extraction and Quantitative Real-Time polymerase chain
reaction (qRT-PCR)
The expression of chondrogenic genes Sex-Determining Region Y-Box
9 Protein (SOX9), aggrecan (ACAN), collagen type II (COL2A1) and
frizzled-related protein 1 (FRZB) and hypertrophy genes collagen type X
(COL10A1) and activin receptor-like kinase 1 (ALK1) [19], were assessed
by qRT-PCR at passage 3. Briefly, messenger RNA was isolated from
cultured cells using an RNeasy kit (Qiagen) and cDNA was generated
using the High-Capacity cDNA Reverse Transcriptase Kit (Applied Bio-
systems), according to manufacturer's recommendations. qRT-PCR
analysis was conducted on a Quant Studio 3 Quantitative Real-Time
PCR System (Applied Biosystems) using SYBR green QuantiTect primer
assays for SOX9, ACAN, COL2A1, FRZB, COL10A1, ALK1 (Qiagen).
Relative gene expression was determined by the comparative Ct method
(2 ΔCt), using the reference genes peptidylprolyl Isomerase A (PPIA) and
TATA-box binding protein (TBP). These reference genes were the two
most stable from a screening test of five genes (data not shown).
2.5. Chondrogenic differentiation and histological analysis
At passage 3, SF cells were induced towards chondrogenic differen-
tiation for 28 days in 3D pellet culture by centrifuging (8 mins at 350g)
2  105 cells and culturing the resulting pellet in chondrogenic medium
which consisted of complete culture medium supplemented with Insulin-
Transferrin-Selenium (1% v/v, Life Technologies), ascorbic-acid
(0.1 mM, Sigma), dexamethasone (10 nM), sodium pyruvate (1 mM),
linoleic acid (20 μM) and Transforming Growth Factor-β1 (10 ng/ml,
PeproTech). Chondrogenic differentiation was assessed by scoring of
toluidine blue-stained cryosections (0–9, with 9 being the highest levels
[20]) and GAG quantitation using the dimethylmethylene blue assay
(DMMB). Spearman's correlation analyses of gene expression after cul-
ture expansion and the positivity of surface markers and the production
of GAGs in the pellets were performed.
2.6. Statistical analysis
All statistical analyses were conducted in GraphPad Prism version 7.
The Shapiro-Wilk normality test revealed that the data for flow cytom-
etry, gene expression, GAG/DNA and histology scores were not normally
distributed, and as a result, non-parametric Spearman's correlations were
used for determining relationships between immunopositivity or gene
expression and the production of GAGs in the pellets. Two-way ANOVAs
were used to determine the difference in means between stage 1 and
stage 2 macrophage positivity in SF cells. Data, unless otherwise stated,
are shown as median with the interquartile range (IR), and p-values less
than 0.05 were considered significant.
3. Results
3.1. Immunoprofile of culture expanded SF cells in early OA patients
Cultured SF cells displayed high median positivity for the MSC
markers CD73 (97.4%, IR 43.1–99.3), CD90 (97.4%, IR 40.0–99.1),
CD105 (98.9%, IR 98.2–99.7) and the immunomodulatory marker
CD106 (91.2%, IR 77.4–96.3). Although CD45, CD19 and HLA-DR were
absent (<1%), CD14 (53.0%, IR 19.0–84.3) and CD34 (23.3%, IR
6.4–35.8) were present with significant patient variation (Fig. 1A).
Strong correlations were found between the presence of CD14 and CD34
(r ¼ 0.7, p ¼ 0.03), and between CD14 and CD106 (r ¼ 0.81, p ¼ 0.003)3
on cultured cells (FigS1 Supplementary Data 1). The chondrogenic
markers CD44 (99.7%, IR 98.2–99.9) and CD151 (99.9%, IR 99.1–99.8)
were positive on all of the culture expanded SF cells from all patients
investigated, whilst CD39 (21.4%, IR 16.7–28.2), CD49c (18.6%, IR
13.6–40.7) and CD166 (17.6, IR 6.1–32.6) showed varying levels of
immunopositivity (Fig. 1B). Cells showed low levels of immunopositivity
for CD271 (3.97, IR 2.9–9.0).
3.2. The chondrogenic capacity of SF cells is variable in early OA patients
SF cells showed considerable variability between patients with
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differentiation. The markers SOX9, ACAN, and ALK1 were highly
expressed, while COL2A1, FRZB and COL10A1 showed minimal or no
expression (Fig. 1C). After chondrogenic induction, SF cells produced a
median of 3.1 μg (IR 2.4–3.4) of GAG/μg of DNA (Figs. 1, 2 and 3A).
Histology indicated variable toluidine blue staining, both between sam-
ples and sometimes within a pellet (Fig. 2B). The strongest toluidine blue
staining was seen in pellets formed from patient 4 which produced
12.7 μg GAG/μg of DNA (SD  4.9), which was supported by the his-
tological analyses. Thus, the mean GAG/DNA results for patient 4 created
an outlier that was 3.4 standard deviations above the mean of all of the
samples.3.3. Correlation analyses between chondrogenic markers and chondrogenic
differentiation
None of the putative chondrogenic surface markers correlated
significantly with the production of GAG by SF cells (Table 3). Due to the
unexpected variability in positivity of CD14, CD73 and CD90 in
expanded SF cells across patients, analyses were run to determine
whether the positivity of these markers was associated with the pro-
duction of GAG by the cells, but no significant correlations were found.
When the outlier of patient 4 was excluded from the analyses, CD90
(r ¼ 0.6, p ¼ 0.03) and CD105 (r ¼ 0.55, p ¼ 0.04) had a moderate
negative correlation with the production of GAG/DNA (Table 3, scat-
terplots found in FigS2 Supplementary Data 2). Similarly, none of the
genetic markers examined correlated with the production of GAG
(DMMB or histology scores) in SF cells after chondrogenic induction, but
when the outlier of patient 4 was excluded, GAG/DNA production
strongly correlates with COL2A1 expression (r ¼ 0.73, p ¼ 0.006)
(Table 3). Interestingly, the cells from patient 4, which produced the
highest amount of GAG, also showed the highest expression of SOX9.Fig. 2. A) Production of GAGs by SF cells. The GAGs from chondrogenic pellets
of SF cells were quantified using the DMMB/DNA assay (n ¼ 15). Error bars
represent the standard deviation of triplicate pellets for the same patient. (B)
Representative images of toluidine blue stained sections of SF cell pellets with
histology scores (n ¼ 10). The images indicate the worst (left), average (central)
and best (right) chondrogenic differentiation in the samples studied using the
Bern scoring system that ranges from 0 to 9 (0 ¼ poor chondrogenesis, 9 ¼ good
chondrogenesis). Scale bar ¼ 200 μm.
4
3.4. Pro-inflammatory and anti-inflammatory monocyte/macrophages are
a subset of non-cultured SF cells
Multichromatic flow cytometry confirmed the presence of CD14þ
cells (3.2% of total SF cells, IR 1.3-27.4) at baseline (stage 1) and post-
cartilage harvest (stage 2) (8.6%, IR 5.0–15.8). For the M1 markers, we
found virtually no CD14þ/CD80þ (0.0%, IR 0.0-0.31) or CD14þ/
CD86þ (0.6%, IR 0-2) co-positive cells at stage 1, with a marginal in-
crease in CD14þ/CD86þ (3.1%, IR 1.28-3) at stage 2 (Fig. 3A and B).
Cells that were CD14þ/CD206þ and CD14þ/CD163þ co-positive were
detected at both stage 1 (1.0, IR 0-10.5 and 1.0%, IR 0-3.4 respectively)
and at stage 2 (1.7%, IR 0.75-7.2 and 1.5%, IR 0.2-2.3 respectively). No
statistical difference between the two stages was found for any of the
markers tested. Further analyses confirmed there to be a subpopulation
of monocyte/macrophages containing both M1 markers, i.e. CD14þ/
CD80þ/CD86þ (Fig. 4). Similarly, co-positivity for M2 markers, i.e.
CD14þ/CD206þ/CD163þ was also observed. Interestingly, some
CD14þ SF cell samples were simultaneously positive for the M1 marker
CD86 and either CD206 or CD163. Whilst CD14þ/CD80þ/CD206þ and
CD14þ/CD80þ/CD163þ cells were not seen at stage 1, a small increase
at stage 2 was detected.
4. Discussion
The aim of this study was to characterise cells found in the SF of
patients at an early stage of OA, categorised as having focal cartilage
injuries, immediately following arthrocentesis and in the plastic-
adherent sub-cultured population. Our findings suggest that the SF of
these patients contains a heterogeneous population of cells. The posi-
tivity of CD14 could indicate the presence of monocytes/macrophage-
like cells, possibly originating from the synovium, infrapatellar fat pad
and/or subchondral bone in the event of deep cartilage defects. The
detection of CD34 also suggests the presence of haematopoietic cells,
endothelial cells or adipose derived mesenchymal stem cells [21]. The
absence of CD19 confirms that lymphocytes (B cells) did not persist in the
culture of SF cells [22], whilst the lack of any HLA-DR positivity suggests
a low state of activation for any monocytes/macrophages present in the
SF cultures. The surface marker CD106 is involved in the recruitment of
immune cells from blood vessels [23], but also identifies a subpopulation
of MSCs with enhanced immunomodulatory properties [24]. High posi-
tivity for CD106, together with its correlation with CD14, could explain
the presence of macrophage-like cells in the SF, i.e. since an increase in
CD106 could engender more infiltration of immune cells into the joint.
The frequency of macrophages in the synovium of the knee joint is known
to be augmented in both the early and late phases of OA, which con-
tributes to the inflammatory state of the joint [25,26]. Another study
assessing the cell surface epitopes of SF cells after acute knee ligament
injury reported a similar lack of lymphocytes, but interestingly revealed a
low positivity (<8%) for CD34, CD45 and CD106 [27]. This data suggests
that the infiltration of immune cells occurs to varying degrees in patients
with different joint injuries and is also likely to vary at different stages of
the disease. The SF cells described in the ligament injury study were
evaluated at an earlier stage in disease progression than in our patients,
which could indicate that the establishment of an inflammatory state
within the joint is progressive and more pronounced in our patients,
when considering the higher relative levels of CD106 and CD34 observed
in our study.
A number of the SF samples investigated in the present study did not
contain cells that met the recommended criteria for MSCs [28] following
culture expansion, due to the positivity of CD73 and CD90 being below
95%, which supports the theory that there is a mixed population of cells
present in the SF of these patients. Furthermore, these results corroborate
observations by another group where human SF-MSCs, obtained before
and after ligament surgery, did not fully meet the immunoprofile criteria
for MSCs [27,28]. The cause of the focal defects is unknown in our cohort
of patients, which makes it difficult to establish a link between initial
Fig. 3. A) Representative scatterplots and histograms of macrophage analysis in fresh SF from stage 1 and stage 2 of patient 16 receiving cell therapy. Multicolour flow
cytometry was used to identify and quantify macrophage subsets using antibodies against CD14 (pan macrophage marker), CD80, CD86 (both M1), CD206 and CD163
(both M2). Gates were established from isotype controls and values in the quadrants represent the percentage of positive cells. (B) Comparison of the macrophage
profiles in matched stage 1 and stage 2 SF samples from patients 16–21 (n ¼ 6).
Table 3
Spearman correlation coefficient values for the correlation between chondro-
genic outcome (GAG/DNA and histology scores) and baseline expression of ge-
netic and surface markers.
GAG/DNA (n ¼ 15) Histology score (n ¼ 9)
r p values r p values
Genetic markers
SOX9 0.02 0.98 0.41 0.31
COL2A1 0.50 0.07a 0.48 0.23
ACAN 0.33 0.25 0.22 0.62
FRZB 0.01 0.97 0.29 0.50
COL10A1 0.17 0.55 0.57 0.14
ALK1 0.07 0.8 0.29 0.48
Surface marker
CD49c 0.20 0.40 0.04 0.90
CD166 0.043 0.88 0.18 0.64
CD39 0.08 0.79 0.25 0.52
CD271 0.44 0.11 0.08 0.85
CD73 0.03 0.91 0.14 0.71
CD90 0.51 0.06a 0.11 0.78
CD105 0.28 0.30a 0.16 0.69
CD14 0.43 0.11 0.38 0.32
CD34 0.18 0.63 0.003 0.99
a When the outlier of patient 4 was excluded from analyses, correlations were
significant as follows: COL2A1 (r ¼ 0.7, p ¼ 0.006); CD90 (r ¼ 0.6, p ¼ 0.03);
CD105 (r ¼ 0.55, p ¼ 0.04).
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trauma and cell infiltration into the joint space. Attempts have beenmade
to understand this process in animal injury models of OA [29–32], but
this requires further research in humans for the improved understanding
of attempted joint repair by endogenous stem cell niches.
Previous research has revealed the presence of cells with chondro-
genic ability in the SF of end-stage OA patients [10], however, only a few
studies have explored these cells following cartilage injury or in the early
stages of OA [9]. In the current study, surface markers and genes known
to be indicative of chondrogenic potency in chondrocytes, bone marrow
MSCs and adipose cells [14], were used to assess SF cells. In comparison,
the expression levels of the chondrogenic genes tested for in the SF cells
(for Sox9, collagen type II, aggrecan and frizzled-related protein 1) were
unsurprisingly lower than what we observed in articular chondrocytes,
whereas the hypertrophic genes (collagen type X and activin
receptor-like kinase 1) were expressed at similar levels in SF cells and
chondrocytes [14]. None of the markers tested correlated with the
chondrogenic ability of SF cells until the statistical outlier (patient 4) was
removed, after which CD90 and CD105 immunopositivity negatively
correlated with GAG/DNA production and COL2A1 expression positively
correlated with GAG/DNA. It is not too surprising that higher COL2A1
expression levels relate to increased pellet GAG content as both are
established indicators of chondrogenic differentiation. However, the
finding that CD90 and CD105 immunopositivity negatively correlates
Fig. 4. A) Representative scatterplots of the co-positivity of M1 and M2 markers on macrophages in the SF of patient 16 at stage 1 and at stage 2. Cells that were
positive for CD14 were gated and used to plot the co-positivity of M1 and M2 markers. Gates were established from isotype controls and values in the quadrants
represent the percentage of positive cells. (B) Comparison of the M1/M2 co-positivity profiles in matched stage 1 and stage 2 SF samples from patients 16–21 (n ¼ 6).
J. Garcia et al. Osteoarthritis and Cartilage Open 2 (2020) 100039with GAG content is interesting as it has been suggested that these
markers relate to enhanced chondrogenic potential [33,34], although
others have disputed this [35]. Patient 4 had no unusual clinical or
biological features to explain the superior chondrogenic ability of their
cells, other than, perhaps, being the youngest patient of the cohort (19
years old). It is noteworthy that the quantity of GAG produced by SF cells6
in the present study was lower than we reported for chondrocytes and
infrapatellar fat pad derived MSCs, but similar to bone marrow and
subcutaneous fat derived MSCs [14]. The heterogeneous metachromatic
staining of the chondrogenic pellets suggests that there may be a sub-
population of SF cells (MSCs, chondrocytes or chondroprogenitor cells)
with enhanced chondrogenic ability.
J. Garcia et al. Osteoarthritis and Cartilage Open 2 (2020) 100039It is believed that MSCs may be recruited from various joint tissues
such as the synovium, bone marrow, fat pads, cartilage and ligaments
when injury or damage occurs within the joint [27,29]. MSCs are also
known to be present in peripheral blood [36] and as such it is possible
that blood derived MSCs could be found in the joint from intra-articular
bleeding. The SF from joints with end-stage OA contains more MSCs than
healthy joints [9] and it could be hypothesised that the patients in the
present study did not have sufficient joint degeneration to trigger the
recruitment of numerous MSCs into the SF. It has been suggested that
chemoattractant molecules released from damaged ligaments could be
responsible for the increase in SF-MSCs noted after ligament surgery
[27]. The patients included in our study had no indication of ligament
damage in addition to their focal cartilage defects and other studies have
shown that damaged cartilage releases chemokines that recruit immune
cells [37–39], but it remains unclear whether MSC infiltration is also
initiated in this process.
To investigate the various subsets of CD14þ macrophages present in
the SF of patients receiving treatment for cartilage injury, we assessed the
positivity of known M1 (CD80 and CD86) and M2 (CD163 and CD206)
markers. To our knowledge, our results are the first to show the co-
existence of cells with both M1 and M2 markers in SF of early OA pa-
tients. The markers CD80 and CD86 are co-stimulatory factors involved
in antigen presentation and T cell activation and are associated with a
pro-inflammatory phenotype [17,18], while CD163 (scavenger receptor)
and CD206 (mannose receptor) are associated with an anti-inflammatory
and wound healing phenotype [15,16], The maturation of macrophages
from circulatory monocytes is mediated by some soluble factors
including tumour necrosis factor-alpha (TNF-α), interleukin-4 (IL-4),
interleukin-10 (IL-10) and interleukin-13 (IL-13); TNF-α would polarise
the cells to an M1 phenotype, while IL-4, IL-10 and IL-13 would polarise
the cells to an M2 phenotype [40]. We have shown that IL-10 and IL-13
are detectable in the SF of patients with cartilage defects [41,42], while
the presence of TNF-α and other pro-inflammatory molecules in OA knee
joints has been widely reported [43]. Intra-articular bleeding could
explain the SF macrophage population. In addition, the presence of
macrophage subsets has been confirmed in the synovium and infrapa-
tellar fat pad in end-stage OA joints [44,45], which could represent a
local source. We found that some macrophages co-express both M1 and
M2 markers, which adds to the growing body of literature challenging
the dichotomous model of macrophage polarisation being either pro- or
anti-inflammatory and indicating that these macrophages can perform
both functions [46,47]. Our results complement the findings of a recent
study investigating SF cells from end-stage OA joints, which similarly
noted the presence of macrophages with overlapping pro- and
anti-inflammatory phenotypes [48]. Assessing the positivity of the
various macrophage subsets in matched samples at baseline and 2–3
weeks after cartilage harvest in ACI has allowed for a rare snapshot of the
cellular response of SF to acute injury and in the presence of established
focal defects. We have previously shown that there is a detectable
response to stage 1 surgery in the SF proteome and for many patients,
acute phase response signalling proteins are significantly upregulated
[49]. There is a likely role for the macrophages identified in this study in
this acute phase response, which warrants further study in a larger
sample cohort.
The co-existence of immune cells and MSCs in the SF of patients with
cartilage injuries and at an early stage of OA development could have
implications for the wound healing and regenerative capacity of a joint.
We previously demonstrated the negative effects of conditioned media
from M1 polarised macrophages on the chondrogenic ability of BM-
MSCs, with a similar inhibitory effect being observed with conditioned
media from OA synovium and infrapatellar fatpad explant cultures [44,
50]. This collective body of work, including the present study, shows that
there could be interplay between macrophages (and other innate im-
mune cells) and MSCs, possibly to orchestrate an endogenous repair.
Longitudinal in vivo studies would be required to disentangle these pro-
cesses of attempted repair, but also to understand when and why this7
repair often fails. The early stages of joint disease offer a window of
opportunity for treatment, but unravelling the phenotypes of SF cells, as
we have in this study, needs to be further investigated.
This investigation has some limitations, the main one being the
relatively small sample size. We also acknowledge that other confound-
ing factors, such as the level of systemic inflammation and the surgery
itself, could have an influence on the phenotype of SF cells. Furthermore,
our study only gives a snapshot of the cellular phenotypes at a given time
of the disease state, and is unlikely to represent the entire spectrum of
different cell states at the various phases of OA progression. Our results
further highlight the disconnect between the expression of key chon-
drogenic markers and the actual chondrogenic output of MSCs.
Comparing our data to SF cells from healthy joints would have been
ideal, however we did not have access to such samples. The phenotype of
SF cells only represents a part of the “bigger picture” of early OA and
other joint tissues, such as the damaged cartilage and inflamed synovium,
would also need to be investigated and compared to the SF cells for a
more comprehensive characterisation.
In conclusion, the results presented here revealed that the SF of pa-
tients with focal cartilage defects contains a mixed population of
adherent cells that likely include monocytes/macrophages, endothelial
cells, synoviocytes, chondrocytes and MSCs. The macrophage subsets in
the SF from this group of patients, which express both pro- and anti-
inflammatory markers, shows the presence of both damaging and
reparative phenotypes, indicative of the cocktail of different signals
present in the joint. Further research into the phenotype of macrophages
within the joint could shed new light on the pathogenesis of OA. Follow-
on studies should be geared towards creating a more detailed timeline of
the cellular mechanisms involved following cartilage injury and under-
standing more fully the ‘stage specific’ roles of the various cellular sub-
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